Tissue microarray technology in breast cancer HER2 diagnostics

Égervári, Kristóf; Szöllősi, Zoltán; Nemes, Zoltán

doi:10.1016/j.prp.2006.12.004

Cited by 31 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The signifi cance of amplifi ed oncogene in breast cancer has been the subject of debate. HER-2/neu(Cerb-B-2) is the gene known to show the highest frequency of amplifi cation, and has in several reports been associated with breast carcinoma progression and clinically aggressive behaviour of BC [22][23][24][25][26][27][28][29][30]. There was inverse relationship in between HER-2/neu over expression and ER/PR receptor status (table 4), similar observation also revealed by other studies [26,27].…”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Significance of Her-2/neu protein over expression in Indian breast cancer patients

et al. 2007

View full text Add to dashboard Cite

Background Racial disparity in presentation and outcome of breast cancer is established but cause is unexplained . Many studies show various molecular markers for racial differences in the prognosis of breast cancer. There is scarcity of data on prognostic signifi cance of HER-2/neu in Indian breast cancer. Aims and ObjectiveTo know incidence and prognostic signifi cance of HER-2/neu expression in Indian patients.To correlate HER-2/neu Expression with other prognostic markers and ER/PR Receptor status. Statistical Analysis Data was analyzed by univariate and multivariate analysis for all prognostic factors. Signifi cance was calculated by using Chi square test and survival analysis by using Kaplan Meier survival curve. Material and MethodsResults The median age of 112 patients was 46.56 (±9.55) years. HER-2/neu over expression was present in 46.37%. Signifi cant correlation was found between HER-2/neu over expression and lymph node status, grade of tumor and ER/ PR receptor status. Median follow up period of 23 months. There was signifi cant tumour free survival advantage (p < 0.01) and overall survival advantage (p < 0.001) in patients with HER-2/neu negative expression.Conclusion HER-2/neu oncogene over expression is higher (46.37%) among Indian patients in comparison to 25-30% shown in most western literature. HER-2/neu oncogene over expression signifi cantly correlates with grade, lymph node involvement, ER/PR status and also affects survival.

show abstract

Section: Discussionsupporting

confidence: 69%

“…Due to cost factor it is still not affordable by Indian patients. Tissue microarrays (TMAs) as current medical research tools signifi cantly lower the costs of immunohistochemical examinations (IHC) and fl uorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability [28].…”

Section: Discussionmentioning

confidence: 99%

Significance of Her-2/neu protein over expression in Indian breast cancer patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…would slightly increase the representativity of TMA analysis. Our observations are in concordance with other studies of steroid hormone receptors and HER-2 in breast carcinomas (24)(25)(26) comparing TMA data with wholesection studies. Furthermore, in a recent study, tumor heterogeneity and TMA sampling for biomarkers have been addressed (27), showing that a single TMA very well reflects the findings within the whole breast tumor.…”

Section: Tissue Microarray Validation In Lung Cancer Researchsupporting

confidence: 92%

Tissue Microarray Validation: A Methodologic Study with Special Reference to Lung Cancer

Karlsson

Bodin²,

Piehl-Aulin

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Although tissue microarray (TMA) studies of histopathologic material have been frequently reported in studies of malignant diseases, the question of sample size (i.e., the diameter and the number of tissue cylinders investigated) has been rarely discussed. This study addresses the methodologic question of sample size in a variety of tumor types. Material and Methods: Material from 29 cases of lung carcinoma (small cell, squamous cell, and adenocarcinomas) was examined immunohistochemically for Ki-67 and p53 expression in virtually constructed cylinders of different diameters. The influence of tissue sample size (i.e., different numbers of virtual cylinders) was also investigated. Results from Ki-67 evaluation were analyzed as a continuous variable, whereas p53 expression was scored. p53 evaluations based on scoring in cylinders versus scoring of whole sections

show abstract

“…Figure 1 shows the immunohistochemical reactions with the different antibodies. According to an increasing number of papers, both 2+ and 3+ cases are to be tested at the DNA level by FISH [12,25,36,[41][42][43][44] . In the present study, 3+ cases not harboring gene amplification were able to be found in all IHC settings, and we believe that those cases still have to be recognized; this suggests that FISH should be performed routinely in both 2+ and 3+ cases.…”

Section: Discussionmentioning

confidence: 99%

“…A possible way to reduce the costs of both IHC and FISH examinations can be the utilization of tissue microarrays (TMAs), as previously described both by our study group and Sapino et al [42,47] . TMAs, mainly used in research, reduce the costs of IHC and FISH examinations while they enable highly standard conditions [31][32] .…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Antibodies in Breast Cancer HER2 Diagnostics

Égervári

Szöllősi

Nemes³

2008

Tumor Biol

Self Cite

View full text Add to dashboard Cite

Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential. Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases. Taking FISH as the endpoint, we calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV) and accuracy for all IHC assays with either taking both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest showed 100% sensitivity and NPV, while the highest specificity, PPV and accuracy was associated with RM-4B5 (97.36, 80 and 95.34%, respectively). The second highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only with 3+ cases, the results were reversed with increased specificity, PPV and accuracy. Our findings suggest that improving sensitivity by using two parallel IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway CB11. Nevertheless, we may consider performing FISH analysis without prior IHC screening.

show abstract

Tissue microarray technology in breast cancer HER2 diagnostics

Cited by 31 publications

References 27 publications

Significance of Her-2/neu protein over expression in Indian breast cancer patients

Significance of Her-2/neu protein over expression in Indian breast cancer patients

Tissue Microarray Validation: A Methodologic Study with Special Reference to Lung Cancer

Immunohistochemical Antibodies in Breast Cancer HER2 Diagnostics

Contact Info

Product

Resources

About